Article
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
Cancer - 1 Oct 2016
Deol Abhinav, Sengsayadeth Salyka, Ahn Kwang Woo, Wang Hai-Lin, Aljurf Mahmoud, Antin Joseph Harry, Battiwalla Minoo, Bornhauser Martin, Cahn Jean-Yves, Camitta Bruce, Chen Yi-Bin, Cutler Corey S, Gale Robert Peter, Ganguly Siddhartha, Hamadani Mehdi, Inamoto Yoshihiro, Jagasia Madan, Kamble Rammurti, Koreth John, Lazarus Hillard M, Liesveld Jane, Litzow Mark R, Marks David I, Nishihori Taiga, Olsson Richard F, Reshef Ran, Rowe Jacob M, Saad Ayman A, Sabloff Mitchell, Schouten Harry C, Shea Thomas C, Soiffer Robert J, Uy Geoffrey L, Waller Edmond K, Wiernik Peter H, Wirk Baldeep, Woolfrey Ann E, Bunjes Donald, Devine Steven, de Lima Marcos, Sandmaier Brenda M, Weisdorf Dan, Khoury Hanna Jean, Saber Wael
Abstract excerpt
BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.